Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Repeat antenatal betamethasone and cardiometabolic outcomes|
|Citation:||Obstetrical and Gynecological Survey, 2018; 73(12):670-672|
|Publisher:||Lippincott Williams & Wilkins|
|Robert D. Cartwright, Jane E. Harding, Caroline A. Crowther, Wayne S. Cutfield, Malcolm R. Battin, Stuart R. Dalziel, Christopher J.D. McKinlay, on behalf of the ACTORDS Follow-up Group|
|Abstract:||Antenatal corticosteroid therapy is one of the most effective interventions for preterm birth, resulting in rapid maturation of fetal organ systems. The Australasian Collaborative Trial of Repeat Doses of Steroids (ACTORDS) revealed that neonatal benefit is greatest when antenatal corticosteroids are administered in repeat doses, which can be used to reduce the incidence and severity of preterm lung disease and other serious neonatal morbidity, with absolute benefits similar to that of an initial course of antenatal corticosteroids.|
|Rights:||© 2018 Wolters Kluwer Health, Inc. All rights reserved.|
|Appears in Collections:||Paediatrics publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.